| Document |
Document Title |
|
WO/2023/213969A1 |
Provided herein are proteins comprising a viral-binding domain and reagents comprising same. In some aspects, the provided proteins and reagents can be used for the purification of viral particles. In some aspects, the provided proteins ...
|
|
WO/2023/215877A1 |
Described herein are compositions and methods for targeted erythroid-specific protein degradation. The compositions described comprise a binding domain for a erythroid protein of interest, e.g., BCL11A, and a binding domain for a erythro...
|
|
WO/2023/212827A1 |
Described herein in aspects is a humanized anti-class II MHC antibody, wherein the humanized antibody binds to class II MHC with similar or increased affinity and/or specificity as compared with a non-humanized anti-MHC class II antibody...
|
|
WO/2023/186079A9 |
Provided are a CD80 protein variant and a fusion protein comprising the CD80 protein variant, which can bind to PD-L1, CTLA-4 and CD28, activate the activity of T lymphocytes, and inhibit the growth and/or proliferation of tumors or tumo...
|
|
WO/2023/213008A1 |
The present invention provides high-strength silk comprising various spider silk proteins and a preparation method therefor. The obtained silk comprises gold silk web spider major ampullate silk proteins MaSp‑g and MaSp‑c. By means o...
|
|
WO/2023/214162A1 |
The present invention relates to peptide ligands, such as bicyclic peptide ligands, specific for transferrin receptor 1 (TfR1). The invention also includes pharmaceutical compositions comprising said peptide ligands and the use of said p...
|
|
WO/2023/213009A1 |
Disclosed is a method for preparing composite silk comprising major ampullate spidroin of Trichonephila clavipes. The method comprises: inoculating 5th instar bombyx mori larvae against a recombinant virus, adding mulberry leaves for fee...
|
|
WO/2023/215829A1 |
The disclosure provides a heteromultimer comprising a first heterodimer that binds to human delta-like ligand 3 (DLL3) and a second heterodimer that binds to human CD3, which can bind to DLL3-expressing cancer cells. The disclosure also ...
|
|
WO/2023/208157A1 |
Provided are a CD19-targeting chimeric antigen receptor and use thereof. Further provided are a CD19-targeting chimeric antigen receptor, a corresponding nucleic acid molecule, a vector, an immune effector cell, a preparation method ther...
|
|
WO/2023/212551A1 |
The present disclosure provides modified cytotoxic T cells (mCTLs), where the mCTLs comprise: a) one or more nucleic acids comprising nucleotide sequences encoding a T-cell receptor (TCR) specific for MHC class I polypeptides that presen...
|
|
WO/2023/207717A1 |
Provided are development and use of a broad-spectrum vaccine for H5N8 avian influenza, and particularly, provided are preparation methods for a recombinant protein vaccine, an inactivated vaccine and a nucleic acid vaccine, and use there...
|
|
WO/2023/210661A1 |
Provided are [0] extracellular vesicles that present at least one cytokine extramembranously; [1] extracellular vesicles that present at least one target factor extramembranously; or [2] extracellular vesicles that present at least one t...
|
|
WO/2023/206938A1 |
Provided is a chimeric antigen receptor targeting CCR8, comprising a signal peptide, an extracellular recognition domain, a transmembrane domain, and a signal transduction domain. The extracellular recognition domain comprises an anti-CC...
|
|
WO/2023/207107A1 |
Provided is a co-agonist of a GLP-1 receptor and a GCG receptor. Also provided are a pharmaceutical composition comprising these compounds, use of these compounds, and a method for treating and/or preventing a metabolic disease or disorder.
|
|
WO/2023/212446A1 |
In one aspect, the present disclosure relates to treating or preventing a respiratory disease or disorder, by administering one or more compositions comprising an isolated polypeptide derived from an alpha Connexin and an anti-viral agen...
|
|
WO/2023/210585A1 |
The present invention provides a means for targeting a substance to motor nerve cells. Provided is a targeting agent for a motor nerve cell synapse including an antibody that can bind to an in-vesicle domain of synaptotagmin 2.
|
|
WO/2023/212687A1 |
Provided herein are systems comprising: (a) an RNA binding moiety; and (b) a gRNA hybrid comprising (i) a complementary region that hybridizes with an mRNA of an active allele of a gene associated with a disorder associated with a decrea...
|
|
WO/2023/204290A1 |
The present invention addresses the problem of providing a new acellular preparation that need not be prepared for each patient individually and can stably and inexpensively achieve a high killing effect on tumor cells. Provided is a m...
|
|
WO/2023/202280A1 |
Provided are an anti-B7H6 scFv antibody, a coding gene thereof, and an application thereof. A B7H6-CAR-T cell includes an antibody or an antigen-binding fragment thereof targeting a B7H6 antigen, containing a heavy chain variable region ...
|
|
WO/2023/205610A2 |
Provided herein are hybrid adeno-associated viruses comprising VP1u and/or VP1/2s region(s) from a first AAV and a VP3 region from a second AAV. Also provided herein are hybrid AAVs and compositions comprising hybrid AAVs that can be use...
|
|
WO/2023/204202A1 |
[Problem] To provide a method for manufacturing, as a protein (mannose-6-phosphate (M6P) low-modification protein) lacking or having a reduced number of M6P that should be originally contained in the glycoprotein, a glycoprotein having, ...
|
|
WO/2023/202237A1 |
The present invention provides a polypeptide targeting HDAC5, and use thereof in the preparation of a formulation for treating or preventing individual tumors. The polypeptide targeting HDAC5 protein is selected from one or more of polyp...
|
|
WO/2023/204148A1 |
The present disclosure provides a method for treating an inflammatory condition, especially an age related inflammatory condition in a mammalian subject in need thereof, which comprises an effective amount of a virus like particle compri...
|
|
WO/2023/201221A1 |
The present invention provides recombinant TIM-4 fusion proteins comprising a domain of TIM-4 and a scFv specific for CD3 and methods of making and using the same. The fusion proteins provided herein may be administered in combination wi...
|
|
WO/2023/197084A1 |
Disclosed herein is a method of identifying a proximity effector polypeptide, the method comprising: transducing an ORFeome library into a plurality of cells, the ORFeome library encoding a plurality of ORFs, wherein each of the ORFs is ...
|
|
WO/2023/199961A1 |
The present invention addresses the problem of providing: immune cells which are favorably capable of survival maintenance and/or cell proliferation under cytokine-free culture conditions or even in a living body in which a high-concentr...
|
|
WO/2023/201174A1 |
Disclosed are methods and kits for eliminating cancer cells and treating cancers by targeting neo splice sites or cryptic exons of oncogenic gene fusions.
|
|
WO/2023/201237A1 |
Provided herein are macromolecules that conditionally induce a cellular effector function (e.g., a biological or therapeutic activity) based on the presence of a disease signature ligand, compositions comprising the same, and methods of ...
|
|
WO/2023/197437A1 |
The present invention belongs to the field of biological medicines, and particularly relates to a chimeric receptor for improving the killing activity of immune cells and an application thereof. Specifically, the present invention provid...
|
|
WO/2023/201148A1 |
Dual-chimeric antigen receptor (CAR) cell systems are disclosed that can be used with adoptive cell transfer to target and kill cancers expressing tumor antigens ("TA") that are also expressed on healthy hematopoietic cells. In some embo...
|
|
WO/2023/197735A1 |
The present invention relates to the field of biomedicine, and specifically relates to a chimeric Fc receptor for a genetically modified pluripotent stem cell and a natural killer cell. Specifically, the structure of the CD64 chimeric re...
|
|
WO/2023/200008A1 |
Provided is a method for producing cultured meat. Cultured meat is produced by culturing animal cells in the presence of bovine basic fibroblast growth factor (bbFGF) produced by using coryneform bacteria as expression hosts.
|
|
WO/2023/197365A1 |
The present invention relates to the technical field of fusion proteins. Provided are a recombinant protein carrying a target protein and autonomously entering a eukaryotic cell, a recombinant expression vector, a recombinant bacterium, ...
|
|
WO/2023/198162A1 |
Provided in the present invention is an anti-splicing mutant of CD16 for enhancing cell function. Specifically, the CD16 mutant of the present invention has an amino acid residue mutation at the following sites corresponding to a wild-ty...
|
|
WO/2023/197079A1 |
Described herein is malarial immunogen or a variant thereof comprising at least a portion of the wild-type PfCSP amino acid sequence lacking a KQ motif. In aspects, the malarial immunogen is lacking a KQP motif. For example, the immunoge...
|
|
WO/2023/197603A1 |
Provided is a tumor treatment solution jointly using a gene-modified NK cell and an antibody. Also provided are a fusion protein and an NK cell expressing the fusion protein and having stronger killing activity. The fusion protein compri...
|
|
WO/2023/195535A1 |
The present invention provides: a stable fibrin clot-soluble protein excellent in production in protein-expressing cells in a serum-free medium and suppressing the production of impurities such as degradation products; a pharmaceutical f...
|
|
WO/2023/196742A1 |
Anti-CD90 antibodies, binding fragments, and uses thereof are described. The provided antibodies and binding fragments can be used to isolate CD90 cells or to target such cells ex vivo or in vivo for a research, a diagnostic, or a therap...
|
|
WO/2023/169555A9 |
The present application relates to a chimeric antigen receptor, containing a first antigen-binding domain and a second antigen-binding domain, the first antigen-binding domain targeting a B cell maturation antigen (BCMA), and the second ...
|
|
WO/2023/196274A1 |
The technology described herein is directed to compositions, methods, and systems for measuring the interactions between RNAs and proteins.
|
|
WO/2023/193767A1 |
The present application relates to an antigen binding protein, and specifically relates to a PD-L1 binding protein and/or relates to a bispecific binding protein capable of binding to PD-L1 and PD-1. The present application further provi...
|
|
WO/2023/193800A1 |
Provided are an antibody/T cell receptor chimera carrying different signal peptides and the use thereof. The provided chimeric polypeptide contains a chain A and a chain B, wherein the chain A contains a first antigen binding domain and ...
|
|
WO/2023/193536A1 |
The present invention belongs to the technical field of biology, and provides a deaminase and an adenine base editor. Also provided are a deaminase mutant and a corresponding adenine base editor. The deaminase mutant comprises multiple a...
|
|
WO/2023/186003A1 |
The present disclosure provides polypeptide conjugates comprising GLP-1 receptor agonist and a peptide linker, and liquid pharmaceutical compositions comprising the same. Methods of using such for treating diseases are also provided.
|
|
WO/2023/185957A1 |
Provided are an antibody, a fusion protein and the use thereof. The antibody comprises a CDR sequence selected from at least one of the following: a CDR sequence of a light chain variable region: SEQ ID NOs: 1-3, SEQ ID NOs: 7-9 and SEQ ...
|
|
WO/2023/186170A1 |
The present application relates to a chimeric antigen of SARS-CoV-2 Delta and Omicron variants, and a preparation method therefor and the use thereof. The recombinant antigen of the present application is formed by: (1) a specific amino ...
|
|
WO/2023/186120A1 |
The present invention relates to a nanobody that specifically binds to serum albumin or an antigen-binding fragment thereof, a derivative comprising the nanobody or the antigen-binding fragment thereof, a nucleic acid encoding the antibo...
|
|
WO/2023/192948A1 |
Some embodiments of the methods and compositions provided herein relate to chimeric cytokine receptors. In some embodiments, a chimeric cytokine receptor can include an IL-7 domain and/or an IL-21 domain. In some embodiments, the chimeri...
|
|
WO/2023/185072A1 |
Provided are an anti-CD7 nanobody and a derivative thereof. The derivative comprises a humanized anti-CD7 nanobody, a chimeric antigen receptor based on a single nanobody, a chimeric antigen receptor based on a double nanobody, a recombi...
|
|
WO/2023/190550A1 |
The present invention provides a chimeric receptor comprising: a first polypeptide which has (i) a first extracellular region binding to a ligand, (ii) a first transmembrane region, and (iii) a first intracellular region derived from an ...
|
